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Abstract: AIMS With ongoing intensive vaccination programme against COVID-19, numerous cases of
adverse reactions occur, some of which represent rare events. Enlargement of the injection sitersquo;s
draining lymph nodes is increasingly reported, but is not yet widely recognised as being possibly associated
with recent vaccination. As patients at risk of a severe course of COVID-19, indicated by their medical
history such as a previous diagnosis of malignancy, receive priority vaccination, newly palpable lymph
nodes raise concerns of disease progression. In this case series, we report on five patients who presented
with enlarged lymph nodes after COVID-19 vaccination. METHODS Sonography guided fine needle
aspiration (FNA) was performed in five patients presenting with PET-positive and/or enlarged lymph
nodes after COVID-19 vaccination with either the Pfizer-BioNTech or Moderna vaccine. RESULTS
COVID-19 vaccination had been carried out in all cases, with an interval of between 3 and 33 days
prior to FNA. Three of five patients had a history of neoplasms. The vaccine was administered into
the deltoid muscle, with subsequent enlargement of either the cervical, supra-, infra- or retroclavicular,
or axillary lymph nodes, in four out of five cases ipsilaterally. In all cases, cytology and additional
analyses showed a reactive lymphadenopathy without any sign of malignancy. CONCLUSIONS Evidence
of newly enlarged lymph nodes after recent COVID-19 vaccination should be considered reactive in the
first instance, occurring owing to stimulation of the immune system. A clinical follow-up according to
the patientrsquo;s risk profile without further diagnostic measures is justified. In the case of preexisting
unilateral cancer, vaccination should be given contralaterally whenever possible. Persistently enlarged
lymph nodes should be re-evaluated (2 to) 6 weeks after the second dose, with additional diagnostic
tests tailored to the clinical context. Fine needle aspiration is a well established, safe, rapid and cost-
effective method to investigate an underlying malignancy, especially metastasis. Recording vaccination
history, including date of injection, site and vaccine type, as well as communicating this information
to treating physicians of different specialties is paramount for properly handling COVID-19 vaccine-
associated lymphadenopathy.
DOI: https://doi.org/10.4414/smw.2021.20557






The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives
4.0 International (CC BY-NC-ND 4.0) License.
Originally published at:
Hagen, Cristina; Nowack, Miriam; Messerli, Michael; Saro, Francesca; Mangold, Felix; Bode, Peter Karl




Original article | Published 20 July 2021 | doi:10.4414/smw.2021.20557
Cite this as: Swiss Med Wkly. 2021;151:w20557
Fine needle aspiration in COVID-19
vaccine-associated lymphadenopathy
Hagen Cristinaa*, Nowack Miriama*, Messerli Michaelb, Saro Francescaa, Mangold Felixc, Bode Peter K.a
a Department of Pathology and Molecular Pathology, University Hospital, University of Zurich, Switzerland
b Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Switzerland
c Clinic of Pulmonology, University Hospital, University of Zurich, Switzerland
Summary
AIMS: With ongoing intensive vaccination programme
against COVID-19, numerous cases of adverse reactions
occur, some of which represent rare events. Enlargement
of the injection site’s draining lymph nodes is increasingly
reported, but is not yet widely recognised as being possi-
bly associated with recent vaccination. As patients at risk
of a severe course of COVID-19, indicated by their med-
ical history such as a previous diagnosis of malignancy,
receive priority vaccination, newly palpable lymph nodes
raise concerns of disease progression. In this case series,
we report on five patients who presented with enlarged
lymph nodes after COVID-19 vaccination.
METHODS: Sonography guided fine needle aspiration
(FNA) was performed in five patients presenting with PET-
positive and/or enlarged lymph nodes after COVID-19
vaccination with either the Pfizer-BioNTech or Moderna
vaccine.
RESULTS: COVID-19 vaccination had been carried out in
all cases, with an interval of between 3 and 33 days prior
to FNA. Three of five patients had a history of neoplasms.
The vaccine was administered into the deltoid muscle,
with subsequent enlargement of either the cervical, supra-
, infra- or retroclavicular, or axillary lymph nodes, in four
out of five cases ipsilaterally. In all cases, cytology and
additional analyses showed a reactive lymphadenopathy
without any sign of malignancy.
CONCLUSIONS: Evidence of newly enlarged lymph
nodes after recent COVID-19 vaccination should be con-
sidered reactive in the first instance, occurring owing to
stimulation of the immune system. A clinical follow-up ac-
cording to the patient’s risk profile without further diagnos-
tic measures is justified. In the case of preexisting uni-
lateral cancer, vaccination should be given contralaterally
whenever possible. Persistently enlarged lymph nodes
should be re-evaluated (2 to) 6 weeks after the second
dose, with additional diagnostic tests tailored to the clinical
context. Fine needle aspiration is a well established, safe,
rapid and cost-effective method to investigate an under-
lying malignancy, especially metastasis. Recording vacci-
nation history, including date of injection, site and vaccine
type, as well as communicating this information to treating
physicians of different specialties is paramount for proper-
ly handling COVID-19 vaccine-associated lymphadenopa-
thy.
Introduction
COVID-19, caused by the severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2), was first registered
in China in the end of 2019 from where it rapidly spread
all over the globe. The first person in Switzerland was test-
ed positive on 25 February 2020, and the World Health Or-
ganization (WHO) declared the disease a pandemic on 11
March 2020 [1]. One year later, more than 170 million cas-
es have been reported to the WHO, with over 3.8 million
fatal outcomes [2]. Battling the spread of the virus is dom-
inating public as well as private life, with healthcare in-
stitutions constantly challenged by the high workload and
management of a novel disease [3]. Researchers have been
fervently pursuing the development not only of treatment
options, but also of vaccines to provide protection against
COVID-19 and eventually end the pandemic [4–6].
Various vaccines are being evaluated, with currently 322
vaccine candidates and 18 in use worldwide [7–10]. So
far, three have been approved in Switzerland (Comirnaty®
by Pfizer-BioNTech on 19 December 2020, COVID-19
Vaccine Moderna® by Moderna on 12 January 2021 and
COVID-19 Vaccine Janssen by Johnson&Johnson on 22
March 2021). Over 2500 million doses have been admin-
istered globally, with more than 6.7 million in Switzerland
alone [11–14]. As the demand for vaccine delivery is im-
mediate and high, the population was vaccinated in a strat-
ified approach. It is known that COVID-19 infections af-
fect more severely people with certain medical conditions,
such as cardiovascular, respiratory, metabolic or immune
disorders [15]. Patients with malignancy also carry a con-
siderably higher risk of infection and complications [16],
making it a priority to vaccinate this group. Besides vac-
cination efficiency, possible adverse events are of concern.
Most adverse events following immunisation (AEFI) occur
locally and are mild and self-limiting (tenderness at the
injection site, reddening, swelling). Systemic AEFI range
from fatigue, headache and myalgia to rarely observed
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phadenopathy may also occur following COVID-19 vacci-
nation and affects mostly ipsilateral cervical, supraclavicu-
lar or axillary lymph nodes corresponding to the drainage
route after injection into the deltoid muscle. Evaluation of
the Moderna COVID-19 vaccine found axillary swelling
or tenderness in 11.6% of vaccinated individuals after the
first and 16% after the second dose, in 1.1% with clinically
detected lymphadenopathy [19]. The Pfizer-BioNTech
COVID-19 vaccine trial registered lymphadenopathy in
0.3% of the study participants [20, 21]. This AEFI is most
likely underdiagnosed and underreported, leading to poten-
tial clinical pitfalls in managing patients who present with
a newly palpable mass.
The aforementioned prioritised vaccination of persons
with previous or ongoing malignancies represents a further
challenge during this COVID-19 pandemic. Newly devel-
oped enlargement of lymph nodes raises the question of
metastatic disease and elicits diagnostic workup such as
imaging or excisional biopsies. Here we describe a case se-
ries of five patients referred to the cytology department for
a fine needle aspiration (FNA) of enlarged lymph nodes to
investigate the presence of neoplastic cells. Our aim is to
enhance awareness of COVID-19 vaccine-associated lym-
phadenopathy and reduce the risk of over-diagnosis as well
as overtreatment in suspicious cases. We subsequently pro-
pose a set of recommendations on how to approach lym-
phadenopathy after COVID-19 vaccination.
Material and methods
Between 16 February and 3 March 2021, five patients
who had recently been vaccinated against COVID-19 with
the vaccine by either Pfizer-BioNTech (Comirnaty®) or
Moderna (COVID-19 Vaccine Moderna®) were referred
for FNA at our institution to evaluate positron emission
tomography (PET)-positive or palpably enlarged lymph
nodes. Informed consent was obtained for anonymous pub-
lishing of diagnostic data in this work. Sonography guided
FNA was performed by two experienced cytopathologists
(MN, FS). The material was processed and triaged accord-
ing to standard protocols [22]. Where indicated, addition-
al analysis was initiated. Flow cytometry was performed
as described before [23]. Clonality analysis followed stan-
dardised guidelines [24].
Results
Patients were referred to our outpatient clinic for FNA of
enlarged painless lymph nodes. Two patients (numbers 1
and 5) underwent a PET / computed tomography (CT) scan
for follow-up after small cell and adenocarcinoma of the
lung. One patient (number 4) was suspected of relapse af-
ter incidental diagnosis of a neuroendocrine tumour of the
appendix 6 years previously. Two patients (numbers 2 and
3) were female healthcare professionals worried about hav-
ing metastatic cancer, namely breast cancer, after detecting
palpably enlarged lymph nodes on the lower neck, and in-
fraclavicular and axillary sites.
All patients presented with palpable or easily detectable
superficial lymph nodes on ultrasound in different loca-
tions, either in cervical level IV, supra-, infra-, or retro-
clavicular regions, and in the axilla. Sonographic imaging
revealed partially hypo- and partially isoechogenic lymph
nodes (fig. 1A). The width ranged from 1.0 to 2.4 cm in
size, with ovoid to rounded shapes, sharp borders and on-
ly partially detectable hilum. Some lymph nodes presented
with suspicious sonographic findings (spherical shape with
loss of hilum) [25] (see also supplementary fig. S2 in the
appendix).
In the detailed anamnesis in our outpatient clinic, all pa-
tients reported that they had been vaccinated against
COVID-19 between 3 and 33 days prior to FNA with
either Comirnaty® from Pfizer-BioNTech or COVID-19
Vaccine Moderna® from Moderna. With the exception of
Patient 5, the vaccine had been administered into the left
deltoid muscle. In four of five patients, the enlargement
of lymph nodes was ipsilateral. In Patient 1, PET/CT scan
showed enlarged and very highly 18F-2-fluorodesoxyglu-
cose (FDG)-active axillary lymph nodes ipsilateral to the
vaccination site and the radiologist already suspected vac-
cine-associated reactive lymphadenopathy when request-
ing further workup. Patient 5 presented with a contralateral
retroclavicular lymph node suspicious for metastasis in a
PET/CT scan with moderate FDG activity, which lead to
referral for a cytopathological evaluation. In the same pa-
tient, axillary lymph nodes ipsilateral to the vaccination
site showed very high FDG-activity (fig. 1B), but were
assumed to be vaccine-associated by the attending radi-
ologist and not further analysed. Simultaneously detected
mediastinal lymph nodes, which were later diagnosed as
metastases by endobronchial ultrasound transbronchial
needle aspiration (EBUS-TBNA), showed identically high
FDG-activity levels. The detailed patient information is
summarised in table 1.
Microscopically, carcinoma metastases could be ruled out
both morphologically and immunohistochemically. The
smears showed a florid reactive lymphadenopathy pattern,
characterised by a mixed lymphoid population with lym-
phocytes at different stages of maturation including many
centroblasts admixed with numerous tingible body
macrophages (fig. 1C) [26]. Immunohistochemistry in Pa-
tient 5 revealed a reactive pattern with predominant CD3-
and CD5-positive T cells, admixed with CD20-positive B
cells without co-expression of CyclinD1, CD5, CD10 or
CD23. CD21 marked dendritic cells. Flow cytometry was
performed in three samples (patients 2–4) and revealed a
T-cell predominant population with 72% CD3-positive T
cells over 23% CD19-positive B cells (fig. 1D), and 79%
CD3-postitve T cells over 19% CD19-positive B cells, re-
spectively, for Patients 3 and 4 (see supplementary fig. S1
in the appendix). One case (Patient 2) showed a predom-
inance of B cells with 55% CD19-positive B cells over
37% CD3-positive T cells. IgH rearrangement polymerase
chain-reaction testing revealed a polyclonal B-cell popula-
tion, consistent with follicular hyperplasia. After 2 months,
the lymphadenopathy had clinically regressed in all pa-
tients.
Discussion
In this case series, we present the cytological findings
of five patients with reactive lymphadenopathy following
COVID-19 vaccination. Vaccine-associated lym-
phadenopathy is a known AEFI of various vaccines [27]
such as influenza [28], human papilloma virus [29, 30],
hepatitis B virus [31], measles-mumps-rubella [32–35],
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Figure 1: A: Sonography of the axilla in Patient 1 revealed an enlarged lymph node. B: Corresponding PET-CT scan in Patient 1 shows axillar
lymph nodes ipsilateral to vaccination site with high FDG activity. D: Flow cytometry in Patient 3 showing a T-cell predominant population with
72% CD3-positive T cells over 23% CD19-positive B cells. C: Smear of fine needle aspiration (FNA) (Papanicolaou staining) showing a mixed
lymphoid population with lymphocytes at different stages of maturation and numerous tingible body macrophages (arrows).































































































































FNA = fine needle aspiration; LA = lymphadenopathy; LN = lymph node; NET = neuroendocrine tumour
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tetanus toxoid [36], smallpox [37], and bacille Calmette-
Guérin [38–40], and has also been found for both the Pfiz-
er-BioNTech and Moderna COVID-19 vaccines [41–48].
Reactive lymphadenopathy has even been suggested to be
a potential indicator for successful immunisation overall,
as it implies activation of the immune system [43, 49, 50].
In radiology and nuclear medicine, enhanced tracer uptake
in reactive lymph nodes after any vaccination is a potential
differential diagnosis in PET/CT scans [51–58] and is also
emerging for COVID-19 vaccines [59–66]. However, there
is little information on cytopathological findings.
Lymphadenopathy occurs in various contexts, summarised
by the MIAMI acronym: malignancies, infections, autoim-
mune disorders, miscellaneous and unusual conditions,
and iatrogenic causes [67]. FNA represents a safe, quick
and cost-efficient tool in the evaluation of cervical lym-
phadenopathy [26]. In a systematic review and meta-analy-
sis of 30 studies, FNA of cervical lymph nodes (total of
782 aspirates) showed a sensitivity of 94.2% and specifici-
ty of 96.9% [68]. However, it must be kept in mind that
subclassification of lymphoma and inaccurate diagnosis of
low grade lymphoma are well known limitations of FNA.
A systematic review of 42 studies reported a median rate
of 66–74% at which FNA and core needle biopsies yielded
a subtype-specific diagnosis of lymphoma [69].
The recently proposed Sydney System for lymph node
FNA cytology provides information on how to approach
lymphadenopathy to ensure results of the best attainable
quality. It provides clear reporting categories with possible
differential diagnosis, and recommends further procedures
depending on the context of presentation [70]. Detailed
clinical information (medical history and physical exami-
nation), as well as results from further diagnostic tests such
as imaging or serology, are crucial in the evaluation of
cytological smears from lymph nodes. Overall, the preva-
lence of malignancy for incidental lymphadenopathy only
amounts to 1.1% [71]. However, as cancer patients are
preferentially vaccinated against COVID-19 because of the
risk of severe course of the disease, vaccine-associated re-
active lymphadenopathy might be misinterpreted as cancer
progression. Thus, FNA can contribute to a rapid and cost-
effective workup of lymphadenopathy.
The currently administered COVID-19 vaccines by Pfizer-
BioNTech and Moderna both use a novel technique in
which messenger RNA (mRNA) encoding the full-length
viral spike protein is encapsulated in lipid nanoparticles to
stimulate the production of the viral protein in the recip-
ient’s own cells, thereby provoking an immune response
[72]. mRNA itself is highly immunogenic, but components
of the lipid nanoparticles such as polyethylene glycol
might also cause the observed reactive lymphadenopathy
[73–76]. Due to the postulated strong immune response af-
ter mRNA COVID-19 vaccination, time spans of lymph
node enlargement have been longer than in previous cases
of vaccine-associated lymphadenopathy [77], where reac-
tions occurred shortly after vaccination and disappeared
rapidly within 14 days [54]. Indeed, we observed intervals
between vaccination and FNA of up to 33 days, which calls
for a longer observation period. Interestingly, other reports
of vaccine-associated lymphadenopathy described mainly
enlarged axillary lymph nodes, which was explained by the
drainage pattern after injection into the deltoid muscle. In
contrast, the enlarged lymph nodes in our patients occurred
at various superficial sites of the upper body. This might be
a result of varying injection techniques, slight deviation of
injection site, or individual variables such as lymph drain-
ing routes and immune responses [78]. Fernández-Prada
and colleagues described a series of cases of supraclavicu-
lar lymphadenopathy after COVID-19 vaccination and at-
tributed these to higher than usual injection into the deltoid
muscle [79], expanding the usual expected sites of vac-
cine-associated lymphadenopathy in patients with a recent
COVID-19 vaccination.
In conclusion, we expect an increase of cases of
COVID-19 vaccine-associated lymphadenopathy as a re-
sult of the ongoing intensive vaccination programme. The
risk of overdiagnosis and overtreatment is especially high
in cancer patients (e.g., head and neck carcinomas, lung,
breast, skin cancer, or lymphoproliferative disease). In this
patient group not only the treating physician but also the
patients themselves are sensitised to palpable masses and
might demand further workup. In this context, we rec-
ommend that patients be actively asked about recent
COVID-19 vaccination [80]. It has been shown that the
currently applied COVID-19 vaccines are safe and like-
wise evoke an immune response in oncological patients
[81–83]. Therefore, whenever possible, vaccination should
be administered contralaterally to the site of malignancy
to avoid confusion regarding lymph node enlargement. In
agreement with our findings and previous data from imag-
ing studies of COVID-19 vaccine-associated lym-
phadenopathy [84–89], we recommend: (1) documentation
of vaccination history, including date, site and type of vac-
cine given; (2) a low threshold for diagnostic procedures
(e.g., ultrasound, FNA) in patients with a known cancer
history; (3) a cautious watch-and-wait approach with fol-
low-up physical examination in otherwise healthy patients;
and (4) further diagnostic tests (e.g., ultrasound) if the
lymph nodes enlarge or persist (2 to) 6 weeks after the sec-
ond vaccination dose. In this context, FNA represents a
fast and accurate tool to guide further management.
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Appendix: Supplementary data
Figure S1: Flow cytometry in Patients 2–4 compared with a control case (48-year-old, unvaccinated female with nonspecific lymphadenopa-
thy).
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Figure S2: Ultrasound findings of Patients 2–4 showing enlarged ovoid to spherical lymph nodes with loss of hilum.
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